Flu Vaccine Research Study
Fast Facts
Received at least one influenza (flu) vaccine during the 2018-2022 flu seasons
Generally Healthy
18-50 Years Old
Compensation Provided
Conducted in Washington, DC
Study Background
Researchers at the Vaccine Research Center (VRC) are conducting a study in Bethesda, MD to better understand the safety, tolerability, and immune response to the investigational Mosaic Hexavalent Influenza Vaccine (FluMos-V2).
The Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) is conducting a Phase I study to evaluate the investigational Mosaic Hexavalent Influenza Vaccine (FluMos-V2) in healthy adults. This study is the first of its kind in humans and aims to assess the safety, tolerability, and immune response to this new flu vaccine. FluMos-V2 is designed to protect against multiple strains of the influenza virus and is a promising candidate in the development of more comprehensive influenza vaccines.
Participants in the study will receive two doses of the FluMos-V2 vaccine, administered by injection into the muscle of the upper arm. Throughout the study, blood samples will be collected to monitor participants’ immune responses and overall health. The study’s goal is to gather critical data on the vaccine’s ability to prompt an immune response and to evaluate its safety profile. Additionally, the study will provide valuable insights into how the vaccine may perform in a diverse, healthy adult population.
There is no risk of infection from participation. There is no virus or bacteria in the product, as it is purely synthetic and created in a lab.
Study Background
Researchers at the Vaccine Research Center (VRC) are conducting a study in Bethesda, MD to better understand the safety, tolerability, and immune response to the investigational Mosaic Hexavalent Influenza Vaccine (FluMos-V2).
The Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID) is conducting a Phase I study to evaluate the investigational Mosaic Hexavalent Influenza Vaccine (FluMos-V2) in healthy adults. This study is the first of its kind in humans and aims to assess the safety, tolerability, and immune response to this new flu vaccine. FluMos-V2 is designed to protect against multiple strains of the influenza virus and is a promising candidate in the development of more comprehensive influenza vaccines.
Participants in the study will receive two doses of the FluMos-V2 vaccine, administered by injection into the muscle of the upper arm. Throughout the study, blood samples will be collected to monitor participants’ immune responses and overall health. The study’s goal is to gather critical data on the vaccine’s ability to prompt an immune response and to evaluate its safety profile. Additionally, the study will provide valuable insights into how the vaccine may perform in a diverse, healthy adult population.
There is no risk of infection from participation. There is no virus or bacteria in the product, as it is purely synthetic and created in a lab.
Additional Information
This study is being conducted to evaluate the safety, tolerability, and immune response to the investigational FluMos-V2 vaccine. The goal is to assess whether this new vaccine can provide broader protection against multiple strains of the influenza virus and offer a more effective alternative to current flu vaccines.
You may be eligible to participate in this study if you meet the following criteria:
Inclusion Criteria:
- Healthy adults aged 18-50 years
- Have received at least one licensed influenza vaccine between the 2018-2022 flu seasons
- Body Mass Index (BMI) ≤ 35 within the 56 days before enrollment
- Agree to not receive the 2025-2026 licensed influenza vaccine during the study
Exclusion Criteria:
- Currently breastfeeding or planning to become pregnant during the study
- Received any licensed influenza vaccine within 6 months prior to enrollment
- Received live attenuated vaccines or mRNA vaccines within 4 weeks prior to enrollment
- History of any conditions listed in the exclusion criteria, based on a physical examination
If you meet these criteria and are interested, you could be eligible to participate in this important study.
If you choose to participate in this study, you will be involved in approximately 10 scheduled clinic visits over the course of 10 months. During these visits, you will receive the investigational FluMos-V2 vaccine twice, administered by needle injection into the muscle of your upper arm. Your blood will be drawn at each follow-up visit to monitor your immune response and overall health.
In addition, you may be asked to provide blood and fluid samples, some of which will be stored for future research purposes. Throughout the study, the researchers will closely monitor your health to ensure your safety and track how your body responds to the vaccine.
As a participant, you can receive up to $3,050, depending on the number and type of visits you complete.
There is no cost for you to participate in our research study.